ABSTRACT

Solid organ and hematologic stem cell transplant recipients are at significant risk of morbidity and mortality caused by invasive fungal infections. Causative fungal pathogens for consideration of prophylaxis and initial empiric therapy are generally based on transplant type, along with the type, degree, and duration of immunosuppression. Classes of antifungal agents most frequently utilized include polyenes, triazoles and echinocandins. The spectrum, formulation, dosing regimen, efficacy, adverse event profile, drug interaction profile, and need for therapeutic drug monitoring must be considered for each patient. This chapter focuses on the selection, administration, and monitoring of antifungal agents for the prevention and treatment of invasive fungal infections in this complex population.